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a b s t r a c t 
Heat shock protein 90 promotes tumor progression and survival and has emerged as a vital therapeutic
target. Previously we reported that the combinatorial treatment of 17AAG / sihsp90 α signiﬁcantly down-
regulated Hsp90 αmRNA and protein levels in Glioblastoma Multiforme (GBM). Here we investigated the
ability of cell penetrating peptide (Tat 48–60 CPP)-mediated siRNA-induced hsp90 α knockdown as a single
agent and in combination with 17-allylamino-17-demethoxygeldanamycin (17-AAG) to induce tumor
growth inhibition in GBM and whether it possessed therapeutic implications. GBM and non-tumorigenic
cells exposed to siRNA and / or 17-AAG were subsequently assessed by qRT-PCR, immunoﬂuorescence,
FACS analysis, quantitative Akt, LDH leakage and cell viability assays. PAGE was performed for serum
stability assessment. A combination of siRNA / 17-AAG treatment signiﬁcantly induced Hsp90 α gene and
protein knockdown by 95% and 98%, respectively, concomitant to 84% Akt kinase activity attenuation,
induced cell cycle arrest and tumor-speciﬁc cytotoxicity by 88%. Efﬁcient complex formation between
CPP and siRNA exhibited improved serum stability of the siRNA with minimal intrinsic toxicity in vitro .
The preliminary in vivo results showed that combination therapy induced hsp90 α knockdown and
attenuated Akt kinase activity in intracranial glioblastoma mouse models. The results imply that RNAi-
mediated hsp90 α knockdown increases 17-AAG treatment efﬁcacy in GBM. In addition, the cytotoxic
response observed was the consequence of downregulation of hsp90 α gene expression, reduced Akt
kinase activity and S-G2 / M cell cycle arrest. These results are novel and highlight the ability of Tat to
efﬁciently deliver siRNA in GBM and suggest that the dual inhibition of Hsp90 has therapeutic potentials.
C © 2013 The Authors. Published by Elsevier B.V. on behalf of Federation of European Biochemical

























 1. Introduction 
Heat shock protein 90 is a vital molecular chaperone involved
in regulating cellular processes by chaperoning its oncogenic clien-
tele including EGFR, PDGFR, Cdks, Raf, Akt and p53 [ 1 , 2 ]. Many of
these signalling proteins are overexpressed or mutated in GBM, indi-
cating Hsp90-dependent tolerance to genetic alterations that would
otherwise be fatal. 17-Allylamino-17-demethoxy-geldanamycin (17-
AAG), a benzoquinone antibiotic and binds to the N-terminal domain
of Hsp90 protein with higher binding afﬁnity than ATP and has been
subsequently shown to attenuate tumor growth, induce cell cycle
arrest and apoptosis [ 1 ]. 
Gene therapy has received major impetus in recent years as RNAi
reaches clinical trials [ 3 ]. Low serum stability, renal clearance, non-
speciﬁc immune stimulation and poor cellular uptake are key factors* Corresponding author. Tel.: + 44 (0) 1772893519; fax: + 44 (0) 1772892929. 
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http://dx.doi.org/10.1016/j.fob.2013.06.002 that have restricted the use of RNAi in systemic applications [ 4 ]. We
have previously combined the application of RNAi using small inter-
fering RNA (siRNA) and the current chemotherapeutic drug temo-
zolomide (TMZ) resulting in signiﬁcant gene knockdown and induced
chemosensitivity in GBM [ 5 ]. Furthermore, a combination of RNAi
and 17-AAG manifested signiﬁcant gene and protein knockdown,
concomitant to suppressed Akt levels and reduced GBM growth [ 6 ].
The effects of combination treatment were tumor-speciﬁc as non-
tumorigenic cells exhibited no signiﬁcant cytotoxicity. Although suc-
cessful RNAi response is relatively straight forward in vitro , achieving
high transfection is challenging in vivo [ 7 ]. 
Cell penetrating peptides (CPP) are short cationic peptides ranging
up to 30 amino acids in length. These peptides, together with siRNA,
bind to the anionic cell membrane and prompts cellular internaliza-
tion through a endocytosis-mediated process [ 8 ]. The therapeutic ap-
plications of non-covalently linked siRNA / CPP complexes (SCC) have
been recently reported in vitro and in vivo [ 9 , 10 ]. The Tat 48–60 is a
short cationic peptide derived from the human immunodeﬁciency
virus type 1 (HIV-1) Tat transcriptional activator protein has been ex-
tensively employed for intracellular delivery of ONs including siRNA
in vitro and in vivo [ 11 ]. ean Biochemical Societies. Open access under CC BY license.




















































aIn this study, we determined the effects of hsp90 α-speciﬁc siRNA 
ith and without 17-AAG on GBM cell growth and survival. Dual 
reatment signiﬁcantly reduced GBM cell growth and the cytotoxi- 
ity was tumor-speciﬁc. This induced growth inhibition was a con- 
equence of reduced Hsp90 α gene expression concomitant with re- 
ressed Akt kinase activity and cell cycle arrest in GBM. 
. Results 
.1. RNAi and 17-AAG induce hsp90 α knockdown in GBM 
To examine the gene silencing potential of the combination treat- 
ent, hsp90 α expression was quantitated by qRT-PCR. U87-MG cells 
reated with SCC showed signiﬁcant hsp90 α downregulation after 
8 h, exhibiting a CPP concentration-dependent knockdown of up to 
0% ( Fig. 1 A). After 72 h, although signiﬁcant gene knockdown was 
chieved at a lower CPP concentration, however, increasing the CPP 
oncentration weakened the RNAi response. The combination treat- 
ent produced a signiﬁcant magnitude of hsp90 α knockdown that 
ncreased with increasing CPP concentration, yielding up to 95% after 
8 h ( p ≤0.001). A similar but slightly weakened RNAi response was 
bserved after 72 h. All the qRT-PCR fragments were also resolved by 
garose gel electrophoresis (2%) (data not shown). 
.2. Combination treatment with RNAi and 17-AAG depletes Hsp90 α
rotein levels in GBM 
To examine whether RNAi and 17-AAG administration resulted in 
sp90 α protein repression in glioblastoma, control and treated cells 
ere categorized into three groups depicting the extent of expres- 
ion, namely, strong ( + + ), weak ( + ) and no expression ( −), taking 
nto consideration the intensity, contrast and sharpness of the image. 
CC exhibited an RNAi response that increased with CPP concentra- 
ion resulting in 84% protein reduction was achieved after 48 h with 
2% exhibiting complete inhibition ( Fig. 1 B). After 72 h, however, the 
esponse declined as 74% protein repression was achieved and only 
0% showed no protein expression. Additionally, the combination 
reatment with siRNA and 17-AAG resulted in 98% and 95% protein 
ownregulation with 52% and 61% resulting in no protein expression 
fter 48 and 72 h, respectively. Administration of 17-AAG resulted in 
0% protein repression including 48% that exhibited complete pro- 
ein downregulation after 48 h. The beneﬁt of concomitant gene and 
rotein inhibition was evident with up to 52% and 61% displaying 
omplete protein downregulation ( p ≤0.001). A statistical compari- 
on revealed a signiﬁcant beneﬁt for the combination therapy against 
7-AAG alone after 48 and 72 h, thus suggesting a potential therapeu- 
ic value of this treatment. 
.3. RNAi and 17-AAG promotes downregulation of Hsp90 clientele Akt 
inase activity 
Since Hsp90 is essential for client protein stability and activity, we 
xamined the effects of the treatment on Akt kinase activity in GBM. 
NAi response mediated by SCC reduced Akt activity by 34% and 17% 
fter 48 and 72 h exposure, respectively ( Fig. 1 C). The combination 
reatment signiﬁcantly reduced Akt kinase activity by 74% and 84% 
fter 48 and 72 h, respectively ( p ≤0.001). U87-MG cells exposed to 
7-AAG alone exhibited a 37% and 39% reduction in Akt activity after 
8 and 72 h. The effects of the combination treatment were statisti- 
ally more signiﬁcant than 17-AAG alone ( p ≤0.05). 
.4. RNAi synergizes with 17-AAG to enhance treatment efﬁcacy in 
lioblastoma 
To examine whether siRNA-mediated gene knockdown exerts an 
dditional efﬁcacy on growth inhibition of GBM, U87-MG cells were treated with increasing concentrations of SCC ranging from 15- to 50- 
fold CPP molar excess to siRNA and 17-AAG. The SCC alone resulted in 
signiﬁcant reduction in tumor cell viability yielding up to 19% growth 
inhibition after 48 h ( Fig. 1 D). On the other hand, SCC showed no 
signiﬁcant beneﬁt on growth inhibition of GBM after 72 h. U87-MG 
cells exposed to 17-AAG alone yielded 49% and 75% growth inhibi- 
tion after 48 and 72 h, respectively. Furthermore, the combination of 
SCC and 17-AAG demonstrated a signiﬁcant cytotoxicity in GBM at all 
CPP concentrations resulting in 88% and 84% tumor growth inhibition 
( p ≤0.001). Statistical analysis revealed a signiﬁcant beneﬁt of adding 
hsp90 α-speciﬁc siRNA to 17-AAG on growth inhibition of GBM com- 
pared to 17-AAG alone ( p ≤0.001). A clear correlation between the 
Hsp90 α mRNA and protein expression proﬁle, Akt activity and cell 
viability was observed in GBM. 
2.5. The effects of SCC and 17-AAG in non-tumorigenic cells 
To determine whether the combination of SCC and 17-AAG pos- 
sesses therapeutic value in the treatment of GBM, SVGp12 cells were 
treated with SCC and 17-AAG and its effects on hsp90 α gene expres- 
sion and cell viability was assessed. qRT-PCR analysis revealed negli- 
gible levels of hsp90 α expression after 48 and 72 h ( Fig. 2 A). Although, 
treatments with SCC and 17-AAG were observed to slightly induce 
hsp90 α levels, its effects on SVGp12 cell growth was somewhat unal- 
tered after 48 and 72 h displaying no more than 7% growth inhibition 
( Fig. 2 B). 
2.6. SCC and 17-AAG causes cell cycle arrest in GBM 
As cell cycle progression is a critical element of growth, FACS anal- 
ysis was performed to determine whether Hsp90 α inhibition results 
in cell cycle arrest in GBM. We examined the effects of SCC, 17-AAG 
and a combination of SCC and 17-AAG after 48 and 72 h. Compared to 
the untreated control, U87-MG cells displayed G1 and S phase arrest 
following 17-AAG exposure and an S phase arrest post SCC treatment 
after 48 and 72 h, respectively ( Fig. 3 ). Furthermore, the combination 
treatment induced accumulation of cells in the G2 / M and S phase af- 
ter 48 and 72 h, respectively ( p ≤0.001). However, the only apparent 
effect of 17-AAG was an S phase arrest after 72 h in SVGp12 cells. 
2.7. CPP does not exhibit acute or long-term toxicity 
To determine whether siRNA efﬁciently binds to the CPP, a gel 
shift assay was performed. The peptide bound to the siRNA in a dose- 
dependent manner was observed to completely retard the siRNA at 
15-fold peptide molar excess ( Fig. 4 A). 
To determine whether CPP alone and SCC exhibit intrinsic toxicity 
that could inﬂuence the observed gene silencing effects, membrane 
disturbance and viability were assessed. An LDH leakage assay was 
used to measure the acute membrane disturbance caused by pep- 
tides at high concentrations. Peptide alone showed no more than 6% 
LDH leakage at 50-fold peptide molar excess to siRNA and at CPP 
concentration of 10 μM ( Fig. 4 B). However, SCC induced ∼15% mem- 
brane leakage at a very high CPP / siRNA molar ratio of 100 or 20 μM 
in GBM, consequently, CPP concentrations used in other experiments 
did not exceed 10 μM. In SVGp12 cells, Tat induced no more than 3% 
LDH leakage at concentrations of 20 μM or 100-fold peptide molar 
excess. In addition, long-term toxicity assessment using CellTiter-Glo 
assay showed that CPP induced no more than 2% growth inhibition in 
U87-MG or SVGp12 cells ( Fig. 4 C). 
Moreover, qRT-PCR analysis revealed a regulatory role of the CPP 
on transcriptional regulation of hsp90 α in GBM ( Fig. 4 D), but not in 
non-tumorigenic cells (data not shown). Increasing concentrations of 
CPP induced hsp90 α levels after 48 and 72 h. On the contrary, CPP 
administration causes marginal protein knockdown at 48 and 72 h 
time points ( Fig. 4 E). Akt kinase activity assessment presented no 
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Fig. 1. A combination of SCC and 17-AAG induces Hsp90 α gene and protein knockdown, loss of Akt kinase activity and growth inhibition in GBM. (A) hsp90 α knockdown 
quantitated by qRT-PCR following treatment with SCC (CPP / siRNA ratio of 15–50) and 17-AAG as single agents or as a dual combination. (B) Hsp90 α protein levels determined 
by immunoﬂuorescence utilizing laser scanning confocal microscopy. For each sample, 150 cells were counted and the protein levels were categorized into three groups namely, 
strong ( + + ), weak ( + ) and no expression ( −). (C) The combination treatment attenuated Akt kinase activity. (D) Cell viability assessment using CellTiter-Glo luminescent cell 
viability assay. Cells administered with DMSO (0.0001% v / v) were used as negative control for 17-AAG treated cells and cells exposed to CPP alone (refer Fig. 4 C) served as a negative 
control for all the treated samples. siRNA represents negative control where cells were exposed to neat siRNA. siRNA corresponds to sihsp90 α. Data values are mean ± SD, n = 3. 
* p ≤ 0.05 and ** p ≤ 0.001 were considered statistically signiﬁcant. 
Fig. 2. Cytotoxic effects of the combination treatment with SCC and 17-AAG in non-tumorigenic cells of neural origin. (A) An assessment of hsp90 α gene expression was performed 
by qRT-PCR. (B) Hsp90 inhibition using siRNA and 17-AAG exhibits minimal cytotoxicity in non-tumorigenic cells. SCC represents CPP / siRNA ratio of 15–50). Data values are mean 
± SD, n = 3. * p ≤ 0.05 and ** p ≤ 0.001 were considered statistically signiﬁcant. 
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Fig. 3. SCC and 17-AAG causes cell cycle arrest in GBM. The cell cycle distribution in treated and control samples was quantitated by FACS analysis using a ﬂow cytometer and 
recording 10,000 events per sample. 1 represents control, 2: siRNA, 3–5: SCC 15–50, 6: 17-AAG, and 7–9: SCC + 17-AAG. Data values are mean ± SD, n = 3. * p ≤ 0.05 and ** p ≤
0.001 were considered statistically signiﬁcant. 
Fig. 4. Cytotoxic effect of the CPP interaction with siRNA. (A) A gel shift assay to conﬁrm that CPP effectively binds to the siRNA. M represents siRNA marker, 0: free siRNA and 
1–20: CPP / siRNA molar ratios. (B) LDH leakage assay to assess membrane integrity of cells treated with increasing concentrations of CPP and different SCC ratios ranging from 3–20 
μM and 15–100 (peptide / siRNA ratio), respectively. Control cells were lysed with LDH assay lysis solution representing 100% LDH leakage was used as a control. (C) Long-term 
toxicity analysis of CPP. (D) CPP induces hsp90 α expression in GBM. (E) The effects of CPP and SCC on Hsp90 α protein expression in GBM (refer Fig. 1 B for legend key). (F) CPP 
exhibits no regulatory effect on Akt kinase activity in GBM. Data values are mean ± SD, n = 3. * p ≤ 0.05 and ** p ≤ 0.001 were considered statistically signiﬁcant. 









































































































 signiﬁcant effect of CPP in GBM at all concentrations used in this
study ( Fig. 4 F). Finally, CPP showed accumulation of GBM cells in the
S phase at various concentrations after 48 and 72 h but exhibited no
effect on cell cycle distribution in SVGp12 cells. 
2.8. Complex formation with CPP improves serum stability of siRNA 
Stability studies were performed to characterize the susceptibility
of aqueous siRNA and SCC in 50% human serum as examined by poly-
acrylamide gel electrophoresis. Neat siRNA was unstable in serum
after 1 h and exhibited complete degradation after 6 h ( Fig. 5 ). In con-
trast, SCC demonstrated improved stability in serum at higher peptide
concentrations. At 30-fold peptide molar excess, siRNA integrity was
maintained after 24 h whereas at 50-fold molar excess, intact siRNA
was detected after 36 h. 
2.9. GBM growth in vivo 
Following intracranial implantation, stained sections of tumor
specimen clearly showed the presence of a tumor resulting in tis-
sue distortion ( Fig. 6 A). Furthermore, tumor tissue exhibited high lu-
ciferase expression compared to normal tissue ( Fig. 6 B). The luciferase
activity in treated samples in vitro manifested a dose-dependent re-
duction with up to 73% luciferase knockdown achieved after 24 h
(data not shown). 
2.10. Combination treatment downregulates hsp90 α and Akt activity 
in vivo 
SCC combined with 17-AAG exhibited 73% hsp90 α knockdown af-
ter 24 h ( Fig. 6 C). The hsp90 α expression in tumor tissue was normal-
ized to GAPDH expression as well as normal brain tissue within each
sample to accurately quantitate gene expression. In xenograft mod-
els, combination treatment exhibited 75% reduction in Akt kinase
activity after 24 h ( Fig. 6 D). The Akt activity in tumor specimens was
normalized to normal brain tissue within each sample to accurately
quantitate the Akt expression. The qRT-PCR and Akt kinase activity
results demonstrate a strong correlation. 
3. Discussion 
In GBM, Hsp90 levels are highly induced to support a range of
activated oncoproteins and signalling pathways that glioblastomas
are dependent on [ 12 ]. Hsp90 α, the inducible isoforms of Hsp90,
is highly expressed at both mRNA and protein levels in glioma cell
lines and tissues but not in normal cell lines and tissues [ 13 ]. This
corroborates Hsp90 α as an anti-glioma therapeutic target. We have
previously demonstrated signiﬁcant siRNA-mediated hsp90 α knock-
down concomitant to induced chemosensitivity in GBM in vitro [ 5 ].
However, the major issue in gene therapy is the poor bioavailability
of the negatively charged siRNA molecules. Commonly used trans-
fection systems such as cationic lipids or viruses have several disad-
vantages; the use of cationic lipids is restricted to in vitro and viruses
have the tendency to stimulate immunogenic responses in vivo [ 14 ].
Likewise, the efﬁcacy of many delivery systems is compromised by
the presence of serum proteins. In this study, the ability of CPP to
promote siRNA-mediated RNAi and subsequently induce growth in-
hibition when combined with 17-AAG was investigated in GBM. 
The SCC signiﬁcantly reduced cell viability after 48 h and induced
hsp90 α knockdown after 48 and 72 h that corroborate the ability of the
CPP to deliver functional siRNA into the cells. The hsp90 α knockdown
failed to impose cytotoxic effects after 72 h which could be attributed
to the lack of siRNA durability [ 15 ], and the protein half-life of 36 h [ 6 ]
rationalizing the necessity of a protein inhibitor to achieve additional
efﬁcacy on growth inhibition. Localization studies of SCC revealeda predominant nuclear accumulation along with diffused cytoplas-
mic staining. Increasing the peptide concentration resulted in higher
siRNA yields in the cytoplasm, an observation that correlated well
with RNAi response in vitro implying that the cytoplasmic localiza-
tion of siRNA is critical for maximum gene knockdown. Interestingly,
SCC repressed Akt activity after 48 and 72 h, however, the Akt activity
levels recovered at higher CPP concentrations. A plausible explana-
tion could be that vital components of the survival signalling pathway
such as Akt may be regulated by other chaperones following Hsp90 α
inhibition. 
A combination of SCC and 17-AAG demonstrated synergistic
growth inhibition to enhance treatment efﬁcacy in GBM as compared
to 17-AAG after 48 and 72 h. While the combination treatment in-
duced hsp90 α knockdown comparable to that of 17-AAG, Hsp90 α
protein expression analysis reveal a beneﬁt of adding SCC as protein
levels were signiﬁcantly depleted compared to 17-AAG alone after 48
and 72 h. The Akt activity was assessed to quantitate the extent of
Hsp90 inhibition [ 16 ]. Similar effects were recorded for Akt activity
where the combination treatment signiﬁcantly downregulated its ac-
tivity. Moreover, results reveal a malign addiction of GBM to Hsp90 α
mainly ascribed to the induced cytotoxicity as a result of SCC and
17-AAG administration. These observations conﬁrmed that the dual
approach to target Hsp90 α yields better anti-tumor effects in GBM
compared to either treatment independently. Similar results were
obtained in a preliminary in vivo study whereby nude mice were uti-
lized as carriers of exogenously introduced human tumor that closely
simulates human disease. Due to the limited numbers of animals
available for this investigation [a control group ( n = 1) and treatment
group ( n = 3)], in vivo data presented are preliminary and requires
additional repeats in order to validate the results. Nonetheless, the
data is encouraging. 
CPP alone did not display a signiﬁcant regulatory effect on the
Akt activity at concentrations of 10 μM that corresponds with its ef-
fects on GBM viability where no long-term toxicity was detected.
Similarly, treatment with CPP or SCC exhibited no cytotoxic effects
in non-tumorigenic cells even when associated with 17-AAG. These
observations indicate that Hsp90 α in SVGp12 cells bears a latent /
uncomplexed conformation which corroborates the lack of the re-
quirement for functional / active chaperones in non-tumor cells de-
marcated by the negligible transcriptional expression. This not only
establishes the dependence of tumors to molecular chaperones for
stabilizing oncogenic clientele responsible for malignant transforma-
tion but also the combination treatment may be critical in a clinical
setting whereby a window of dosing can be established to primarily
target glioblastoma cells. 
Cyclin-dependent kinase 4 (cdk4), a serine / threonine kinase func-
tions when bound to active Hsp90 and regulates the G1 cell cycle
progression once activated by Akt [ 17 ]. Similarly, Hsp90 client cdk2
kinase plays an essential role in DNA replication and S / G2 transition
[ 18 ]. Cell division cycle 2 kinase (cdc2) is responsible for G2 / M transi-
tion and requires functional Hsp90 for its activity [ 1 ]. The combination
treatment induced a G2 / M arrest and an S phase arrest after 48 and
72 h, respectively. Results suggest that SCC and 17-AAG-induced cell
cycle arrest was the consequence of Hsp90 α gene expression down-
regulation and Akt activity attenuation. Moreover, the disparity in
cell cycle distribution could be due to a change in conformation of
the chaperone complexes associated with these kinases at different
time points. CPP exhibited an S phase arrest in GBM but not in non-
tumorigenic cells which may indicate non-speciﬁc interference with
the transcriptional regulation of S / G2 transition proteins such as cy-
clin A and cdk2. 
CPP exhibited no long-term toxicity at concentrations used in this
study which contradicts its effect on hsp90 α transcription levels in
GBM. These could be uncharacterized effects of the CPP on the tran-
scriptional regulation of hsp90 α, on par with previous observations
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Fig. 5. SCC improves serum stability of siRNA. M represents siRNA marker and 0 indicates free siRNA. This is representative of three such independent experiments. 
Fig. 6. SCC and 17-AAG induce hsp90 α knockdown and attenuate Akt kinase activity in vivo . (A) H & E stained tissue sections ( n = 2) and (B) luciferase quantitation indicate 












i 19 ]. Additionally, since the CPP is derived from the DNA binding do- 
ain of HIV-1 trans -activator protein, it is conceivable that it may 
irectly interferes with the gene transcription [ 11 ]. 
Presently, 17-AAG is in phase II / III clinical trials in adults with 
olid tumor malignancies [ 20 ]. These results collectively indicate that 
he dual targeting of Hsp90 using RNAi and protein inhibitors possess 
nti-tumor activity in GBM. The combination treatment provided ad- 
itional efﬁcacy on growth inhibition of glioblastoma cells compared 
o 17-AAG alone. In addition, the cytotoxic response observed was 
he consequence of downregulation of Hsp90 α gene and protein ex- 
ression, reduced Akt kinase activity and S-G2 / M cell cycle arrest. 
he tumor-speciﬁc response described herein suggests that the dual 
nhibition of Hsp90 may have therapeutic potential in GBM. 4. Materials and methods 
4.1. Cell culture 
Human Glioblastoma Multiforme (U87-MG) and human non- 
tumorigenic (SVGp12) cell lines were purchased from the European 
Collection of Cell Cultures and the American Type Culture Collection, 
respectively. The cells were propagated in EMEM (Lonza) containing 
FBS (10%), l -glutamine (2 mM), non-essential amino acids (1% v / v), 
and sodium pyruvate (1 mM) and maintained in a humidiﬁed incuba- 
tor at 37 ◦C with 5% CO 2 . Cultures were restricted to 5–7 passages for 
all the experiments. 
4.2. Peptide preparation 
The Tat 48–60 CPP was prepared using a standard strategy as de- 
scribed previously [ 21 ]. The amino acid sequence of the CPP was 

























































































 H -GRKKRRQRRRPPQ- NH 2 (MW: 1718.06). 
4.3. Treatment with siRNA and 17-AAG 
The siRNA speciﬁc to Hsp90AA1 gene with the sequence: sense,
(5 ′ ) CGUGAUAAAGAAGUAAGCGtt (3 ′ ); and antisense, (5 ′ ) CGCU-
UACUUCUUUAUCACGtt (3 ′ ) was resuspended in nuclease-free water
to achieve a stock concentration of 100 μM (Ambion, UK). 
U87-MG and SVGp12 cells were seeded in 96-well plates or 25 cm 2
culture ﬂasks 24 h prior to treatment. The siRNA / CPP complexes (SCC)
were prepared by mixing siRNA (200 nM) with increasing CPP con-
centrations giving rise to siRNA:peptide molar ratios of 1:15–1:50 in
serum-free medium at 37 ◦C for 30 min. Fresh serum-supplemented
medium was added to the cells after 4 h and incubated for a further
48 and 72 h. For combination treatment, 17-AAG was added following
the initial 4 h incubation to achieve a ﬁnal concentration of 0.225 μM.
For the in vivo experiments, SCC (5 mg / kg) were formed in nuclease-
free water at 50-fold peptide molar excess in half the injection volume
(100 μl) using 0.5 mM siRNA and 10 mM CPP stock solutions. After
the 30 min incubation, 100 μl of 10.8% mannitol solution was added
to SCC and injected into the tail-vein of the mice. Subsequently, the
mice were injected with 17-AAG (i.p., 80 mg / kg). Mice treated with
luciferase siRNA (sense: 5 ′ ACGCCAAAAACAUAAAGAAAG3 ′ and anti-
sense: 5 ′ UUCUUUAUGUUUUUGGCGUCU3 ′ ) and 17-AAG were used as
negative controls and the left striatums were used as normal brain
tissues. 
4.4. Cell viability assay 
The percent of viable cells was assessed using CellTiter-Glo ®
luminescent cell viability assay (Promega) as described previously
[ 6 ]. Brieﬂy, U87-MG and SVGp12 cells were seeded at a density of
1000 cells / well in 96-well plates in triplicates 24 h prior to treatment
with SCC and 17-AAG and the luminescent signal was recorded using
Tecan GENios Pro ® (Tecan, Austria). 
4.5. qRT-PCR analysis 
Isolation of mature mRNA and cDNA synthesis was performed as
described previously [ 6 ]. Gene speciﬁc cDNA primers ( hsp90 α sense:
5 ′ tctggaagatccccagacac 3 ′ , antisense: 5 ′ agtcatccctcagccagaga 3 ′ ; and
GAPDH sense: 5 ′ gagtcaacggatttggtcgt 3 ′ , anti-sense: 5 ′ ttgattttg-
gagggatctcg 3 ′ ) were obtained from TIB MOLBIOL (Germany) designed
using the Primer3 software ( http: // primer3.wi.mit.edu / ) and using
the gene sequence (NM 002046.4) obtained from NCBI. The standard
nucleotide BLAST was performed using the GAPDH primer sequence
and the human genomic + transcript nucleotide database available
from BLAST that showed 1 hit for transcripts which was Homo sapi-
ens GAPDH transcript variant 1 (NM 002046.4) showing 100% iden-
tity. It is unlikely that pseudogene interference would occur since the
mRNA Isolation Kit (Roche Life Sciences, UK) ensures high purity of
mRNA (free of DNA and other RNAs) which was subsequently used
for cDNA synthesis and ampliﬁcation. qRT-PCR was performed us-
ing FastStart DNA Master PLUS SYBR Green 1 as described previously
[ 13 ]. The hsp90 α expression proﬁles were normalized to the GAPDH
expression and plotted as a percentage. 
4.6. Immunoﬂuorescence 
A standard protocol was followed for immunoﬂuorescence de-
scribed in depth in a previous publication [ 6 ]. The primary mono-
clonal antibody and FITC-conjugated secondary antibody were ob-
tained from Cambridge Bioscience (UK). The images were taken using
Axiovert 200M LSM 510 laser scanning confocal microscope (Carl
Zeiss Ltd.) and analyzed using the Zeiss LSM Image Browser software
(Carl Zeiss Jena GmbH). 4.7. Akt / PKB kinase activity assay 
Protein extraction, quantitation and Akt kinase activity assess-
ment was performed as described previously [ 6 ]. 
4.8. Cell cycle analysis 
U87-MG and SVGp12 cells were seeded at a density of
1 × 10 5 cells / T25 ﬂask 24 h prior to treatment with SCC and 17-AAG.
Cells were harvested, washed in PBS and ﬁxed in ice-cold ethanol
(70%). After 30 min, cells were incubated in PBS supplemented with
propidium iodide (50 μg / ml; Sigma, UK) and RNase A (100 μg / ml;
Sigma, UK) for 30 min at room temperature. The DNA content was
analyzed by FACSAria ﬂow cytometer (Becton Dickinson, UK) and the
cell cycle proﬁles were obtained using the FACSDiva software (Becton
Dickinson). 
4.9. Gel mobility assay 
SCC was prepared as described earlier at molar ratios ranging from
1:1 to 1:20 (siRNA:peptide) and were subjected to electrophoresis on
15% TBE poly-acrylamide gel (Bio-Rad, UK) in TBE buffer at 100 V
under non-denaturing conditions and stained with ethidium bro-
mide (0.5 μg / ml) and analyzed by UV-transilluminator GENE GENIUS
Bioimaging system (Syngene). 
4.10. Membrane disturbance measurements 
The membrane integrity was measured using the In Vitro Toxicol-
ogy Assay Kit according to manufacturer’s instructions (TOX7; Sigma,
UK). U87-MG and SVGp12 cells (1 × 10 4 / well) were seeded in 96-
well plates 24 h prior to treatment with increasing concentrations CPP
or SCC in serum-free medium for 30 min at 37 ◦C. The samples were
centrifuged and transferred to a clean 96-well ﬂat bottom plate. LDH
assay mixture was added and the absorbance measured at 490 nm us-
ing Tecan GENios Pro ®. Serum-free medium without cells was used
as a blank and untreated cells lysed with LDH Assay Lysis Solution
(1 / 10 total volume) was used as a control. 
4.11. Serum stability of siRNA 
Neat siRNA (1 μg) and SCC were incubated in EMEM with hu-
man serum (50%) at 37 ◦C. Aliquots (20 μl) were taken at 1, 3, 6, 24,
and 36 h intervals and supplemented with Proteinase K (200 μg / ml;
Sigma, UK) and SDS (0.5% w / v). After 1 h incubation at 37 ◦C that
facilitates segregation and digestion of the CPP, the samples were
stored at −80 ◦C. The siRNA was extracted from the SCC using phenol /
chloroform / isoamyl alcohol (25:24:1; Sigma, UK) and analyzed on
15% TBE polyacrylamide gel in TBE buffer (1 × ) at 100 V under non-
denaturing conditions. The gels were stained with ethidium bromide
and images were developed by UV-transilluminator GENE GENIUS
Bioimaging system. 
4.12. RNAi experiments in vivo 
A luciferase expressing cell line (U87-MG-luc2; Caliper Life Sci-
ences) was cultured and propagated as stated above. The intracra-
nial implantation of U87-MG-luc2 cells into the right striatums was
performed utilizing U87-MG-luc2 cells (1 × 10 6 cells / 5 μl of fresh
media without serum) were injected into the right striatums of ho-
mozygous female nude mice using a stereotaxic frame at coordinates
A = + 1, L = + 2, V = + 3.5 from Bregma. Once tumor growth was
detected, the mice were injected with SCC and 17-AAG and the tis-
sues were harvested after 24 h and stored at −80 ◦C immediately.
























Ror luciferase quantitation, protein was extracted using Reporter Ly- 
is Buffer (Promega, Sweden) and quantitated using DC Protein As- 
ay according to manufacturer’s instructions (Bio-Rad). qRT-PCR and 
kt kinase activity was performed as described previously. For H&E 
taining, tissue specimens collected were frozen immediately in a 
sobutanol bath on dry ice. The tissue sections were mounted on glass 
lides and stained with haematoxylin and eosin. All the procedures 
or animal care and tumor cell implantation followed approved ani- 
al protocols and guidelines of the Estonian Laboratory Animal Ethics 
ommittee (approval number 19 dated 25th September 2009, num- 
er 69 and 70 dated 9th February 2011). 
.13. Statistical analysis 
The data presented are the mean of three independent experi- 
ents ± SD (unless stated otherwise) and was analyzed using the 
ASW Statistics 18 package using the One-Sample Student’s T -test 
nd Paired-Sample T -test. A p value of * p ≤0.05 and ** p ≤0.001 was 
onsidered as statistically signiﬁcant. 
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